2073
We report a 31-year-old women with recurrent Hodgkin's lymphoma and unrecognized HMSN-1 who developed severe motor neuropathy 3 weeks after the first cycle of treatment including 2 mg of vincristine.
 a 31-year-old women with recurrent Hodgkin's lymphoma and unrecognized HMSN-1: Subject; 31-year-old: Subject.Age; women: Subject.Gender; unrecognized HMSN-1: Subject.Disorder; severe motor neuropathy: Effect; 3 weeks after the first cycle of treatment including 2 mg of vincristine: Treatment; recurrent Hodgkin's lymphoma: Treatment.Disorder; 3 weeks: Treatment.Time_elapsed; 2 mg: Treatment.Dosage; vincristine: Treatment.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 a 31-year-old women with recurrent Hodgkin's lymphoma and unrecognized HMSN-1: Subject; 31-year-old: Subject.Age; women: Subject.Gender; unrecognized HMSN-1: Subject.Disorder; severe motor neuropathy: Effect; 3 weeks after the first cycle of treatment including 2 mg of vincristine: Treatment; recurrent Hodgkin's lymphoma: Treatment.Disorder; 3 weeks: Treatment.Time_elapsed; 2 mg: Treatment.Dosage; vincristine: Treatment.Drug